<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Research and Public Health1661-78271660-4601MDPI pmcid: 7400365 doi: 10.3390/ijerph17144951ijerph-17-04951 : Review" exact="Hepatitis" post="C Reinfection in People Who Inject Drugs in Resource-Limited"/>
 <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Hepatitis" post="C (HCV) is a global pandemic. The World Health"/>
 <result pre="direct-acting antiviral (DAA) therapies are highly effective at eliminating HCV" exact="infections" post="and have few side effects, medical professionals and policymakers"/>
 <result pre="where at least 50% of participants had DAA treatment for" exact="primary" post="HCV infection. Pooled reinfection rate was calculated across all"/>
 <result pre="studies met eligibility criteria. Most studies were conducted in six" exact="upper" post="middle-income countries (Mexico, Romania, Russia, Taiwan, Georgi, and Brazil)"/>
 <result pre="countries (Mexico, Romania, Russia, Taiwan, Georgi, and Brazil) and one" exact="lower" post="middle-income country (Bangladesh) with a total of 7665 participants."/>
 <result pre="and Brazil) and one lower middle-income country (Bangladesh) with a" exact="total" post="of 7665 participants. No study included information from PWID"/>
 <result pre="the same strain). The follow-up time of people cured from" exact="primary" post="chronic HCV infection ranged from 12 weeks to 6.6"/>
 <result pre="same strain). The follow-up time of people cured from primary" exact="chronic" post="HCV infection ranged from 12 weeks to 6.6 years."/>
 <result pre="The follow-up time of people cured from primary chronic HCV" exact="infection" post="ranged from 12 weeks to 6.6 years. The pooled"/>
 <result pre="and evidence-based programs. While rates of reinfection among PWID who" exact="complete" post="DAA treatment in upper and lower middle-income countries were"/>
 <result pre="rates of reinfection among PWID who complete DAA treatment in" exact="upper" post="and lower middle-income countries were similar or lower than"/>
 <result pre="reinfection among PWID who complete DAA treatment in upper and" exact="lower" post="middle-income countries were similar or lower than rates observed"/>
 <result pre="treatment in upper and lower middle-income countries were similar or" exact="lower" post="than rates observed in PWID in high-income countries, the"/>
 <result pre="comprehensive and not place restrictions on PWID in these settings." exact="hepatitis C" post="reinfection people who inject drugs upper-middle income country lower-middle"/>
 <result pre="acting antiviral (DAA) regimens have radically changed the treatment of" exact="hepatitis C" post="virus (HCV) infection. Introduced in 2014, these highly effective"/>
 <result pre="people who inject drugs (PWID) [1]. Despite these advances, detectable" exact="viral" post="loads following HCV treatment (also known as recurrence) have"/>
 <result pre="Reinfection occurs when a strain of HCV distinct from the" exact="primary" post="infecting strain is detected after HCV cure, or sustained"/>
 <result pre="HCV RNA that remains below the limit of detection in" exact="peripheral" post="blood samples during treatment but rebounds after treatment cessation"/>
 <result pre="blood samples during treatment but rebounds after treatment cessation [3]." exact="Spontaneous" post="clearance, or the elimination of virus without the use"/>
 <result pre="use of medication, occurs around 25% of the time with" exact="primary" post="infection and around 40% in reinfection [4]. Differentiating between"/>
 <result pre="of medication, occurs around 25% of the time with primary" exact="infection" post="and around 40% in reinfection [4]. Differentiating between reinfection"/>
 <result pre="that analyze the HCV strain and compare results to the" exact="primary" post="infection. Emboldened by the entry of DAA regimens, the"/>
 <result pre="initiated in 2016 the Global Health Sector Strategy (GHSS) for" exact="Viral" post="Hepatitis to eliminate HCV by 2030, with a focus"/>
 <result pre="in 2016 the Global Health Sector Strategy (GHSS) for Viral" exact="Hepatitis" post="to eliminate HCV by 2030, with a focus on"/>
 <result pre="Strategic Direction aims to increase information for focused action (identifying" exact="hepatitis" post="epidemics and the target populations to treat), and the"/>
 <result pre="and enhances the positive consequences of treatment, including adherence to" exact="substance use disorder" post="treatment and housing/employment stability [7]. This hesitancy among providers"/>
 <result pre="enhances the positive consequences of treatment, including adherence to substance" exact="use disorder" post="treatment and housing/employment stability [7]. This hesitancy among providers"/>
 <result pre="before and after SVR to distinguish reinfection by a separate" exact="viral" post="strain from the primary infection; however, the high cost"/>
 <result pre="to distinguish reinfection by a separate viral strain from the" exact="primary" post="infection; however, the high cost of deep sequencing may"/>
 <result pre="deep sequencing may preclude its use in resource-limited settings [8,9]." exact="Simple" post="genotyping identifies segments of the highly variant regions (~35%"/>
 <result pre="segments of the highly variant regions (~35% variability) of the" exact="viral" post="RNA to classify the tested strain as one of"/>
 <result pre="as one of seven major types and 67 subtypes [10,11]." exact="Simple" post="genotyping of primary infection and reinfection is limited though"/>
 <result pre="seven major types and 67 subtypes [10,11]. Simple genotyping of" exact="primary" post="infection and reinfection is limited though as it can"/>
 <result pre="major types and 67 subtypes [10,11]. Simple genotyping of primary" exact="infection" post="and reinfection is limited though as it can only"/>
 <result pre="subtypes [10,11]. Simple genotyping of primary infection and reinfection is" exact="limited" post="though as it can only distinguish viral strains if"/>
 <result pre="and reinfection is limited though as it can only distinguish" exact="viral" post="strains if the individual is not reinfected with the"/>
 <result pre="population, two strains (1a and 4a), are dominant [12]. A" exact="limited" post="number of circulating strains can reduce the accuracy of"/>
 <result pre="gene sequencing. The third method involves measuring the HCV RNA" exact="viral" post="load or calculating the copies of virus per milliliter"/>
 <result pre="differentiate reinfection from relapse [8,9]. Despite its significant limitations, HCV" exact="viral" post="load testing is the least expensive method of determining"/>
 <result pre="36 studies (one of which was a multi-country trial) included" exact="upper" post="middle-income countries; the remainder only drew data from high-income"/>
 <result pre="risk of or living with HCV, particularly among those in" exact="African" post="and Asian LMICs [19]. To better understand the scope"/>
 <result pre="terms and synonymous free text to capture the concepts of" exact="hepatitis C," post="reinfection, recurrence, and drug use by people who inject"/>
 <result pre="an additional review of the LILAC database-a database for Latin" exact="American" post="and Caribbean health science literature, due to a lack"/>
 <result pre="due to a lack of published studies in Latin and" exact="Central" post="America and the Caribbean. Our Ovid MEDLINE search is"/>
 <result pre="abstracted directly or calculated (the number of reinfections divided by" exact="total" post="PY) from data included in the reports. The results"/>
 <result pre="seven studies were conducted across multiple sites, including the following" exact="lower" post="middle-, and upper middle-income countries: Mexico, Romania, Russia, Taiwan,"/>
 <result pre="conducted across multiple sites, including the following lower middle-, and" exact="upper" post="middle-income countries: Mexico, Romania, Russia, Taiwan, Georgia, Bangladesh, and"/>
 <result pre="the United States. We observed an inverse association between HCV" exact="infection" post="rates and country income level (World Bank category and"/>
 <result pre="participants using and not using OST services, and found a" exact="lower" post="rate of reinfection (0.6 cases per 100PY for OST"/>
 <result pre="found that reinfection rates measured in studies of PWID in" exact="upper" post="and lower middle-income countries were comparable or lower than"/>
 <result pre="reinfection rates measured in studies of PWID in upper and" exact="lower" post="middle-income countries were comparable or lower than the reinfection"/>
 <result pre="PWID in upper and lower middle-income countries were comparable or" exact="lower" post="than the reinfection rates of PWID in high-income countries."/>
 <result pre="LMIC settings. The variance among these studies, along with the" exact="absence of" post="studies measuring reinfection rates among PWID in low-income countries,"/>
 <result pre="may influence the measured reinfection rates seen among PWID in" exact="upper" post="and lower middle-income countries. Past epidemiological studies have shown"/>
 <result pre="the measured reinfection rates seen among PWID in upper and" exact="lower" post="middle-income countries. Past epidemiological studies have shown that higher"/>
 <result pre="Our review of studies suggests that the testing interval for" exact="recurrent" post="HCV viremia (e.g., every 24 weeks versus 12 weeks)"/>
 <result pre="weeks) may play a role in reinfection rate. Due to" exact="viral" post="clearance of the reinfection, longer testing intervals between assessments"/>
 <result pre="clearance of the reinfection, longer testing intervals between assessments for" exact="recurrent" post="viremia can result in lower measured reinfection rates. Among"/>
 <result pre="testing intervals between assessments for recurrent viremia can result in" exact="lower" post="measured reinfection rates. Among the reviewed studies, longer testing"/>
 <result pre="studies, longer testing intervals did appear to be associated with" exact="lower" post="reinfection rates supporting this finding. Similarly, the length of"/>
 <result pre="While the role of longer follow-up needs to be clarified," exact="lower" post="reinfection rates may be observed because those who are"/>
 <result pre="of the highest risk individuals may also lead to a" exact="lower" post="reinfection rate. Notably different among the studies was the"/>
 <result pre="data about HCV reinfection rates in low-income countries and the" exact="limited" post="data available about HCV reinfection rates in middle-income countries."/>
 <result pre="data available about HCV reinfection rates in middle-income countries. This" exact="deficiency" post="undermines policy makersâ€™ efforts to develop clinically appropriate treatment"/>
 <result pre="weakens global efforts to address socioeconomic health disparities. Given the" exact="limited" post="data on HCV reinfection rates in PWID in resource-limited"/>
 <result pre="epidemic. This study has some limitations. First, there were a" exact="limited" post="number of studies outlining reinfection rates in middle-income countries"/>
 <result pre="the general population (not PWID) and are comparable or even" exact="lower" post="than those of studies in high-income countries [37,38,39,40,41,42]. 5."/>
 <result pre="declare no conflict of interest. References References 1.AsherA.K.PortilloC.J.CooperB.A.Dawson-RoseC.VlahovD.PageK.A.Clinicians views of" exact="hepatitis C" post="virus treatment candidacy with direct-acting antiviral regimens for people"/>
 <result pre="The MALACHITE-I/II trialsJ. Hepatol.201664192810.1016/j.jhep.2015.08.01526321288 3.BourliereM.GaneE.J.JacobsonI.GordonS.C.SulkowskiM.S.McNabbB.L.ReddyK.R.Long-term follow up of patients with" exact="chronic" post="HCV and no or minimal fibrosis shows low risk"/>
 <result pre="the Gilead SVR registryHepatology201766Suppl. 1518A519A28390159 4.KabergM.NaverG.HammarbergA.WeilandO.Incidence and spontaneous clearance of" exact="hepatitis C" post="virus (HCV) in people who inject drugs at the"/>
 <result pre="inject drugs at the Stockholm Needle Exchange-Importance for HCV eliminationJ." exact="Viral" post="Hepat.2018251452146110.1111/jvh.1296929998522 5.collab: WHOGlobal Health Sector Strategy on Viral Hepatitis"/>
 <result pre="HCV eliminationJ. Viral Hepat.2018251452146110.1111/jvh.1296929998522 5.collab: WHOGlobal Health Sector Strategy on" exact="Viral" post="Hepatitis 2016â€&quot;2021: Towards Ending Viral HepatitisWHOGeneva, Switzerland2016 6.MartinelloM.DoreG.J.MatthewsG.V.GrebelyJ.Strategies to"/>
 <result pre="eliminationJ. Viral Hepat.2018251452146110.1111/jvh.1296929998522 5.collab: WHOGlobal Health Sector Strategy on Viral" exact="Hepatitis" post="2016â€&quot;2021: Towards Ending Viral HepatitisWHOGeneva, Switzerland2016 6.MartinelloM.DoreG.J.MatthewsG.V.GrebelyJ.Strategies to reduce"/>
 <result pre="WHOGlobal Health Sector Strategy on Viral Hepatitis 2016â€&quot;2021: Towards Ending" exact="Viral" post="HepatitisWHOGeneva, Switzerland2016 6.MartinelloM.DoreG.J.MatthewsG.V.GrebelyJ.Strategies to reduce hepatitis C virus reinfection"/>
 <result pre="Hepatitis 2016â€&quot;2021: Towards Ending Viral HepatitisWHOGeneva, Switzerland2016 6.MartinelloM.DoreG.J.MatthewsG.V.GrebelyJ.Strategies to reduce" exact="hepatitis C" post="virus reinfection in people who inject drugsInfect. Dis. Clin."/>
 <result pre="characteristics on persons who use drugs pursuit of care for" exact="hepatitis C" post="virus infectionJ. Subst. Abuse Treat.2019102333910.1016/j.jsat.2019.04.00931202286 8.KumarA.RajputM.K.PaliwalD.YadavA.ChhabraR.SinghS.Genotyping &amp;amp; diagnostic methods"/>
 <result pre="virus infectionJ. Subst. Abuse Treat.2019102333910.1016/j.jsat.2019.04.00931202286 8.KumarA.RajputM.K.PaliwalD.YadavA.ChhabraR.SinghS.Genotyping &amp;amp; diagnostic methods for" exact="hepatitis C" post="virus: A need of low-resource countriesIndian J. Med. Res.201814744545510.4103/ijmr.IJMR_1850_1630082568"/>
 <result pre="A need of low-resource countriesIndian J. Med. Res.201814744545510.4103/ijmr.IJMR_1850_1630082568 9.PhamS.T.BullR.A.BennettJ.M.RawlinsonW.D.DoreG.J.LloydA.R.WhiteP.A.Frequent multiple" exact="hepatitis C" post="virus infections among injection drug users in a prison"/>
 <result pre="low-resource countriesIndian J. Med. Res.201814744545510.4103/ijmr.IJMR_1850_1630082568 9.PhamS.T.BullR.A.BennettJ.M.RawlinsonW.D.DoreG.J.LloydA.R.WhiteP.A.Frequent multiple hepatitis C virus" exact="infections" post="among injection drug users in a prison settingHepatology2010521564157210.1002/hep.2388521038409 10.ZeinN.N.Clinical"/>
 <result pre="injection drug users in a prison settingHepatology2010521564157210.1002/hep.2388521038409 10.ZeinN.N.Clinical significance of" exact="hepatitis C" post="virus genotypesClin. Microbiol. Rev.20001322323510.1128/CMR.13.2.22310755999 11.GrahamC.S.SwanT.A path to eradication of"/>
 <result pre="C virus genotypesClin. Microbiol. Rev.20001322323510.1128/CMR.13.2.22310755999 11.GrahamC.S.SwanT.A path to eradication of" exact="hepatitis C" post="in low- and middle-income countriesAntivir. Res.2015119899610.1016/j.antiviral.2015.01.00425615583 12.AkiyamaM.J.LipseyD.HeoM.AgyemangL.NortonB.L.HidalgoJ.LoraK.LitwinA.H.Low hepatitis C"/>
 <result pre="of hepatitis C in low- and middle-income countriesAntivir. Res.2015119899610.1016/j.antiviral.2015.01.00425615583 12.AkiyamaM.J.LipseyD.HeoM.AgyemangL.NortonB.L.HidalgoJ.LoraK.LitwinA.H.Low" exact="hepatitis C" post="reinfection following direct-acting antiviral therapy among people who inject"/>
 <result pre="opioid agonist therapyClin. Infect. Dis.201910.1093/cid/ciz69331346609 13.CuypersL.PerezA.B.ChuecaN.Aldamiz-EchevarriaT.AladosJ.C.Martinez-SapinaA.M.GarciaF.Relapse or reinfection after failing" exact="hepatitis C" post="direct acting antiviral treatment: Unravelled by phylogenetic analysisPLoS ONE201813e020126810.1371/journal.pone.020126830044871"/>
 <result pre="antiviral treatment: Unravelled by phylogenetic analysisPLoS ONE201813e020126810.1371/journal.pone.020126830044871 14.HoornenborgE.CoyerL.N.AchterberghR.C.A.vanderLoeffM.F.S.BruistenS.deVriesH.J.C.AMsteH.I.V.T.E.High incidence of" exact="hepatitis C" post="virus (re-) infections among PrEP users in the Netherlands:"/>
 <result pre="phylogenetic analysisPLoS ONE201813e020126810.1371/journal.pone.020126830044871 14.HoornenborgE.CoyerL.N.AchterberghR.C.A.vanderLoeffM.F.S.BruistenS.deVriesH.J.C.AMsteH.I.V.T.E.High incidence of hepatitis C virus (re-)" exact="infections" post="among PrEP users in the Netherlands: Implications for prevention,"/>
 <result pre="Int. AIDS Soc.201821115 15.SimmonsB.SaleemJ.HillA.RileyR.D.CookeG.S.Risk of late relapse or reinfection with" exact="hepatitis" post="c virus after achieving a sustained virological response: A"/>
 <result pre="A meta-analysisJ. Hepatol.201910.1016/S0618-8278(19)31466-5 17.KonermanM.A.RogersM.KenneyB.SingalA.G.TapperE.SharmaP.WaljeeA.Opioid and benzodiazepine prescription among patients with" exact="cirrhosis" post="compared to other forms of chronic diseaseBMJ Open Gastroenterol.20196e00027110.1136/bmjgast-2018-000271"/>
 <result pre="prescription among patients with cirrhosis compared to other forms of" exact="chronic" post="diseaseBMJ Open Gastroenterol.20196e00027110.1136/bmjgast-2018-000271 18.HeffernanA.CookeG.S.NayagamS.ThurszM.HallettT.B.Scaling up prevention and treatment towards"/>
 <result pre="Gastroenterol.20196e00027110.1136/bmjgast-2018-000271 18.HeffernanA.CookeG.S.NayagamS.ThurszM.HallettT.B.Scaling up prevention and treatment towards the elimination of" exact="hepatitis" post="C: A global mathematical modelLancet20193931319132910.1016/S0140-6736(18)32277-330704789 19.collab: WHOAccess to Hepatitis"/>
 <result pre="of hepatitis C: A global mathematical modelLancet20193931319132910.1016/S0140-6736(18)32277-330704789 19.collab: WHOAccess to" exact="Hepatitis" post="C Testing and Treatment for People Who Inject Drugs"/>
 <result pre="Prisonsâ€&quot;A Global PerspectivePolicy BriefWHOGeneva, Switzerland2019 20.FosterG.R.DoreG.J.WangS.GrebelyJ.ShermanK.E.BaumgartenA.ConwayB.JacksonD.AsselahT.GschwantlerM.et al.Glecaprevir/pibrentasvir in patients with" exact="chronic" post="HCV and recent drug use: An integrated analysis of"/>
 <result pre="phase III studiesDrug Alcohol Depend.201919448749410.1016/j.drugalcdep.2018.11.00730529905 21.HuangM.LiuW.SuL.WuC.WuP.YangS.ChangS.Hepatitis C virus re-infection after" exact="viral" post="clearance of HCV among HIV-positive patients with recent HCV"/>
 <result pre="21.HuangM.LiuW.SuL.WuC.WuP.YangS.ChangS.Hepatitis C virus re-infection after viral clearance of HCV among" exact="HIV-positive" post="patients with recent HCV infection in TaiwanJ. Int. AIDS"/>
 <result pre="viral clearance of HCV among HIV-positive patients with recent HCV" exact="infection" post="in TaiwanJ. Int. AIDS Soc.201821Suppl. 815710.1002/jia2.25187 22.LathamN.H.DoyleJ.S.PalmerA.Y.VanhommerigJ.W.AgiusP.GoutzamanisS.LiZ.PedranaA.GottfredssonM.BouscaillouJ.et al.Staying hepatitis"/>
 <result pre="HCV infection in TaiwanJ. Int. AIDS Soc.201821Suppl. 815710.1002/jia2.25187 22.LathamN.H.DoyleJ.S.PalmerA.Y.VanhommerigJ.W.AgiusP.GoutzamanisS.LiZ.PedranaA.GottfredssonM.BouscaillouJ.et al.Staying" exact="hepatitis C" post="negative: A systematic review and meta-analysis of cure and"/>
 <result pre="Policy201974697510.1016/j.drugpo.2019.09.00231542689 24.ReddyK.R.PolS.ThuluvathP.J.KumadaH.ToyotaJ.ChayamaK.LevinJ.LawitzE.GadanoA.GhesquiereW.et al.Long-term follow-up of clinical trial patients treated for" exact="chronic" post="HCV infection with daclatasvir-based regimensLiver Int.20183882183310.1111/liv.1359628941023 25.RockstrohJ.K.OrkinC.VianiR.M.WylesD.LuetkemeyerA.F.LazzarinA.LazzarinA.Soto-MalaveR.NelsonM.R.BhaganiS.R.et al.Safety and"/>
 <result pre="al.Long-term follow-up of clinical trial patients treated for chronic HCV" exact="infection" post="with daclatasvir-based regimensLiver Int.20183882183310.1111/liv.1359628941023 25.RockstrohJ.K.OrkinC.VianiR.M.WylesD.LuetkemeyerA.F.LazzarinA.LazzarinA.Soto-MalaveR.NelsonM.R.BhaganiS.R.et al.Safety and efficacy of"/>
 <result pre="Â± dasabuvir with or without ribavirin in patients with human" exact="immunodeficiency" post="virus-1 and hepatitis C virus genotype 1 or genotype"/>
 <result pre="or without ribavirin in patients with human immunodeficiency virus-1 and" exact="hepatitis C" post="virus genotype 1 or genotype 4 coinfection: TURQUOISE-I Part"/>
 <result pre="TURQUOISE-I Part 2Open Forum Infect. Dis.20174ofx15410.1093/ofid/ofx15428948180 26.SarrazinC.IsakovV.SvarovskaiaE.S.HedskogC.MartinR.ChodavarapuK.BrainardD.M.MillerM.D.MoH.MolinaJ.M.et al.Late relapse versus" exact="hepatitis" post="c virus reinfection in patients with sustained virologic response"/>
 <result pre="online: https://ssrn.com/abstract=3220107 or http://dx.doi.org/10.2139/ssrn.3220107(accessed on 10 January 2020)10.1016/S1473-3099(19)30264-6 31.RossiC.ButtZ.A.WongS.BuxtonJ.IslamN.YuA.DarvishianM.GilbertM.WongJ.collab: BC" exact="Hepatitis" post="Testers Cohort TeamHepatitis C virus reinfection after successful treatment"/>
 <result pre="modelling studyBMC Infect. Dis.20171716210.1186/s12879-017-2256-528222681 34.EckmanM.H.WardJ.W.ShermanK.E.Cost effectiveness of universal screening for" exact="hepatitis C" post="virus infection in the era of direct-acting, pangenotypic treatment"/>
 <result pre="Infect. Dis.20171716210.1186/s12879-017-2256-528222681 34.EckmanM.H.WardJ.W.ShermanK.E.Cost effectiveness of universal screening for hepatitis C" exact="virus infection" post="in the era of direct-acting, pangenotypic treatment regimensClin. Gastroenterol."/>
 <result pre="Dis.20171716210.1186/s12879-017-2256-528222681 34.EckmanM.H.WardJ.W.ShermanK.E.Cost effectiveness of universal screening for hepatitis C virus" exact="infection" post="in the era of direct-acting, pangenotypic treatment regimensClin. Gastroenterol."/>
 <result pre="among people with HIV/HCV coinfection and people who inject drugsCurr." exact="HIV/AIDS" post="Rep.20171411012110.1007/s11904-017-0358-828432579 36.MartinelloM.BartlettS.DoreG.BopageR.FinlaysonR.BakerD.MatthewsG.Universal access to DAA therapy paves theway for"/>
 <result pre="with HIV in AustraliaJ. Hepatol.201868Suppl. 1S312S31310.1016/S0168-8278(18)30843-2 37.GrebelyJ.HajarizadehB.LazarusJ.V.BruneauJ.TreloarC.collab: International Network on" exact="Hepatitis" post="in Substance UsersElimination of hepatitis C virus infection among"/>
 <result pre="1S312S31310.1016/S0168-8278(18)30843-2 37.GrebelyJ.HajarizadehB.LazarusJ.V.BruneauJ.TreloarC.collab: International Network on Hepatitis in Substance UsersElimination of" exact="hepatitis C" post="virus infection among people who use drugs: Ensuring equitable"/>
 <result pre="International Network on Hepatitis in Substance UsersElimination of hepatitis C" exact="virus infection" post="among people who use drugs: Ensuring equitable access to"/>
 <result pre="Network on Hepatitis in Substance UsersElimination of hepatitis C virus" exact="infection" post="among people who use drugs: Ensuring equitable access to"/>
 <result pre="and care for allInt. J. Drug Policy20197211010.1016/j.drugpo.2019.07.01631345644 38.Falade-NwuliaO.SulkowskiM.S.MerkowA.LatkinC.MehtaS.H.Understanding and addressing" exact="hepatitis C" post="reinfection in the oral direct-acting antiviral eraJ. Viral Hepat.20182522022710.1111/jvh.1285929316030"/>
 <result pre="addressing hepatitis C reinfection in the oral direct-acting antiviral eraJ." exact="Viral" post="Hepat.20182522022710.1111/jvh.1285929316030 39.KellyD.Hepatitis C viraemia after apparent spontaneous clearanceLancet2016387196810.1016/S0140-6736(16)30184-227203661 40.KerkerianG.AlimohammadiA.RaycraftT.ConwayB.Repeated"/>
 <result pre="C viraemia after apparent spontaneous clearanceLancet2016387196810.1016/S0140-6736(16)30184-227203661 40.KerkerianG.AlimohammadiA.RaycraftT.ConwayB.Repeated spontaneous clearance of" exact="hepatitis C" post="virus infection in the setting of long-term non-progression of"/>
 <result pre="after apparent spontaneous clearanceLancet2016387196810.1016/S0140-6736(16)30184-227203661 40.KerkerianG.AlimohammadiA.RaycraftT.ConwayB.Repeated spontaneous clearance of hepatitis C" exact="virus infection" post="in the setting of long-term non-progression of HIV infectionInfect."/>
 <result pre="apparent spontaneous clearanceLancet2016387196810.1016/S0140-6736(16)30184-227203661 40.KerkerianG.AlimohammadiA.RaycraftT.ConwayB.Repeated spontaneous clearance of hepatitis C virus" exact="infection" post="in the setting of long-term non-progression of HIV infectionInfect."/>
 <result pre="42.VickermanP.GrebelyJ.DoreG.J.Sacks-DavisR.PageK.ThomasD.The more you look, the more you find: Effects of" exact="hepatitis C" post="virus testing interval on reinfection incidence and clearance and"/>
</results>
